Targeting ACC1, via genetic knockdown, small-molecule inhibition, or dietary lipid restriction, disrupts lipid homeostasis and primes cells for apoptosis, thereby enhancing sensitivity to Venetoclax, a BCL-2 inhibitor, in AML and solid tumor models [59]. The gene discussed is BCL2; the disease is acute myeloid leukemia.